KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Ibrahim Yawe, Fiona Cresswell, Abraham Siika, Josphat Kosgei, Reena Shah, Logashvari Naidoo, Kimton Opiyo, Caroline Otike, Karlien Möller, Max Okwero, Charity Wambui, Veerle Van Eygen, Perry Mohammed, Fafa Addo Boateng, Nicholas I Paton, CARES trial team

Nat Med 32(1) 168-177

PMID41188524
PMCIDPMC12823427
DOI10.1038/s41591-025-04041-7
发表日期2025-11-04
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图;Extended Data Fig. 1:非 KM 图;Extended Data Fig. 2:身体组成变化图。
摘要

摘要

Evaluation of the durable efficacy and safety of long-acting injectable therapy for HIV is needed in African populations. In a multicenter, open-label phase 3b trial, 512 African adults with HIV-1, stable on first-line oral therapy, with screening plasma viral load (VL) <50 copies ml-1 and without past virologic failure were randomized (1:1) to continue oral therapy or switch to cabotegravir (600 mg) and rilpivirine (900 mg) intramuscular injections every 8 weeks (optional 4-week oral lead-in). VL was monitored every 24 weeks. Here the primary outcome for our analysis up to 96 weeks was VL <50 copies ml-1, using the Food and Drug Administration snapshot algorithm (noninferiority margin 10%) in the intention-to-treat exposed population. At 96 weeks, 247/255 (97%) in the long-acting group and 250/257 (97%) in the oral therapy group had VL <50 copies ml-1 (difference -0.4%; 95% confidence interval -3.1% to 2.0%), demonstrating noninferiority. Adverse events of severity grade ≥3 occurred in 41/255 (16%) in the long-acting group and in 22/257 (9%) in the oral therapy group, mostly considered unrelated to the study drug; only one treatment-related adverse event in the long-acting group led to a decision to discontinue treatment (injection-site abscess). Cabotegravir and rilpivirine long-acting therapy produced durable virologic suppression, met the prespecified noninferiority endpoint compared with oral therapy and demonstrated an acceptable safety and tolerability profile. Long-acting therapy may be considered for use in African treatment programs. PACTR registration: 202104874490818.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1CONSORT diagram. HBsAg, hepatitis B surface antigen; anti-HBc, antibody against hepatitis B virus core antigen. *For assessing eligibility for per-protocol population, the duration of the injection delay excludes days when oral bridging was used, if any. Figure adapted with permission from ref. 8 , Elsevier.
非 KM Figure
Fig. 2Subgroup analysis of viral suppression in the long-acting and oral therapy groups. Proportion of participants with viral suppression below 50 copies per milliliter at week 96, as classified by the FDA snapshot algorithm, shown by randomly assigned treatment group and prespecified subgroups. The point estimate for each subgroup represents the weighted risk difference between the proportion with viral suppression in each treatment group, and the error bars represent the 95% CI for those risk differences. These estimates are obtained using Cochran–Mantel–Haenszel-weighted Miettinen and Nurminen method, without adjustment for third-drug class, including all participants with data available for that subgroup classification. The widths of the CIs have not been adjusted for multiple comparisons and cannot be used to infer treatment effects. The P value is for a two-sided test of homogeneity using the Cochran–Mantel–Haenszel method; a P value of less than 0.05 may indicate evidence of heterogeneity across levels of a stratum, although the threshold has not been adjusted for multiple testing and cannot be used to infer differences in treatment effect between subgroups.
非 KM Figure
Extended Data Fig. 1Timing of injections in the long-acting therapy group. Timing of injections in 255 participants in the long-acting group in relation to the target date, until the time of withdrawal from the trial (3 participants), death (1 participant) or switch to standard treatment (for virological failure in 3 participants and adverse events in 2 participants). The target date for all injections was set at the time of randomisation (4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96 weeks from randomisation). For one participant who interrupted all ART at day 7 (due to incarceration) and had the first injection day at day 125 (delay of 97 days), the target date was determined from the time of the first injection day. For 10 additional participants at one site who had injection delays of more than 14 days, from the time of each injection delay the target date for each subsequent injection was determined from the date of last injection plus 56 days (plus 28 days if the initial injection was delayed); with the target reset using the same principle at the time of each subsequent injection. There were 29 injections that were delayed > 14 days from the target date (occurring in 25 participants; 4 participants had two injections delayed > 14 days, none of which were consecutive injections). The interval from the target date to each delayed injection was 15 to 21 days for 20 injections; 22 to 28 days for 7 injections and > 28 days for 2 injections. Oral lead in with cabotegravir and rilpivirine was extended by 16 days in 1 participant to cover a period of travel before the initial injection; oral bridging was used to cover periods of travel in 2 participants when return to the site was not possible (one with cabotegravir and rilpivirine for 28 days and one with dolutegravir and rilpivirine for 19 days); and oral bridging was used to replace one injection to allow resolution of an injection site abscess in one participant (cabotegravir and rilpivirine for 56 days). Of the 25 participants with one or more injections delayed > 14 days from the target date, 22 had viral loads < 50 copies/ml at all measurement time points; three had a single measured viral load ≥ 50 copies/ml at one timepoint (66, 108 and 381 copies/ml) and all had VL < 50 copies/ml at week 96.
非 KM Figure
Extended Data Fig. 2Changes in total fat mass and total lean mass measured by DEXA. Change in fat and lean mass from baseline to week 48 and week 96 in complete cases. Values shown are mean change within each treatment group, by sex.
非 KM Figure